Renovorx announces acceptance of four clinical data abstracts at the 2023 asco gastrointestinal cancers (asco gi) symposium

Los altos, calif.--( business wire )--renovorx, inc. (nasdaq: rnxt), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced the acceptance of four clinical data abstracts supporting its lead oncology product candidate, renovogem, and its proprietary renovorx trans-arterial micro-perfusion (renovotamp) therapy platform to be presented at the 2023 asco gastrointestinal cancers symposium (asco gi). the symposium is to be held on january 19-21, 2023 in san francisco, california and online.
RNXT Ratings Summary
RNXT Quant Ranking